193 related articles for article (PubMed ID: 35974197)
1. Aliivibrio fischeri L-Asparaginase production by engineered Bacillus subtilis: a potential new biopharmaceutical.
Bento HBS; Paiva GB; Almeida MR; Silva CG; Carvalho PJ; Tavares APM; Pedrolli DB; Santos-Ebinuma VC
Bioprocess Biosyst Eng; 2022 Oct; 45(10):1635-1644. PubMed ID: 35974197
[TBL] [Abstract][Full Text] [Related]
2. Characterization and applications of glutaminase free L-asparaginase from indigenous Bacillus halotolerans ASN9.
Shafqat I; Shahzad S; Yasmin A; Chaudhry MT; Ahmed S; Javed A; Afzal I; Bibi M
PLoS One; 2023; 18(11):e0288620. PubMed ID: 38015853
[TBL] [Abstract][Full Text] [Related]
3. Biochemical characterization of glutaminase-free L-asparaginases from Himalayan Pseudomonas and Rahnella spp. for acrylamide mitigation.
Patial V; Kumar S; Joshi R; Singh D
Int J Biol Macromol; 2024 Feb; 257(Pt 2):128576. PubMed ID: 38048933
[TBL] [Abstract][Full Text] [Related]
4. Rational engineering and insight for a L-glutaminase activity reduced type II L-asparaginase from Bacillus licheniformis and its antileukemic activity in vitro.
Zhou Y; Shen J; Chi H; Zhu X; Lu Z; Lu F; Zhu P
Int J Biol Macromol; 2024 Feb; 257(Pt 2):128690. PubMed ID: 38092107
[TBL] [Abstract][Full Text] [Related]
5. Glutaminase-free L-asparaginase production by
Freire RKB; Mendonça CMN; Ferraro RB; Moguel IS; Tonso A; Lourenço FR; Santos JHPM; Sette LD; Pessoa Junior A
Prep Biochem Biotechnol; 2021; 51(3):277-288. PubMed ID: 32921254
[TBL] [Abstract][Full Text] [Related]
6. L-asparaginase production review: bioprocess design and biochemical characteristics.
Castro D; Marques ASC; Almeida MR; de Paiva GB; Bento HBS; Pedrolli DB; Freire MG; Tavares APM; Santos-Ebinuma VC
Appl Microbiol Biotechnol; 2021 Jun; 105(11):4515-4534. PubMed ID: 34059941
[TBL] [Abstract][Full Text] [Related]
7. Microbial production, molecular modification, and practical application of l-Asparaginase: A review.
Wang Y; Xu W; Wu H; Zhang W; Guang C; Mu W
Int J Biol Macromol; 2021 Sep; 186():975-983. PubMed ID: 34293360
[TBL] [Abstract][Full Text] [Related]
8. Engineering and Expression Strategies for Optimization of L-Asparaginase Development and Production.
Shishparenok AN; Gladilina YA; Zhdanov DD
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894901
[TBL] [Abstract][Full Text] [Related]
9. A new extracellular glutaminase and urease-free L-asparaginase from Meyerozyma guilliermondii.
Ratuchne A; Izidoro SC; Beitel SM; Lacerda LT; Knob A
Braz J Microbiol; 2023 Jun; 54(2):715-723. PubMed ID: 36917331
[TBL] [Abstract][Full Text] [Related]
10. Towards development of biobetter: L-asparaginase a case study.
Tripathy RK; Anakha J; Pande AH
Biochim Biophys Acta Gen Subj; 2024 Jan; 1868(1):130499. PubMed ID: 37914146
[TBL] [Abstract][Full Text] [Related]
11. Homology modeling and molecular docking studies to decrease glutamine affinity of Yarrowia lipolytica L-asparaginase.
Darvishi F; Beiranvand E; Kalhor H; Shahbazi B; Mafakher L
Int J Biol Macromol; 2024 Apr; 263(Pt 2):130312. PubMed ID: 38403216
[TBL] [Abstract][Full Text] [Related]
12. Production, purification and kinetic characterization of glutaminase free anti-leukemic L-asparaginase with low endotoxin level from novel soil isolate.
Prakash P; Singh HR; Jha SK
Prep Biochem Biotechnol; 2020; 50(3):260-271. PubMed ID: 31762381
[TBL] [Abstract][Full Text] [Related]
13. Production and Anticancer Activity of an L-Asparaginase from Bacillus licheniformis Isolated from the Red Sea, Saudi Arabia.
Alrumman SA; Mostafa YS; Al-Izran KA; Alfaifi MY; Taha TH; Elbehairi SE
Sci Rep; 2019 Mar; 9(1):3756. PubMed ID: 30842557
[TBL] [Abstract][Full Text] [Related]
14. Recombinant production and characterization of L-glutaminase (glsA) as a promiscuity therapeutic enzyme.
Simay S; Akbarzadeh-Khiavi M; Pourseif MM; Barar J; Safary A; Omidi Y
Appl Microbiol Biotechnol; 2022 Sep; 106(17):5511-5524. PubMed ID: 35876873
[TBL] [Abstract][Full Text] [Related]
15. Isolation, Purification, Characterisation and Application of L-ASNase: A Review.
Paul T; Mondal A; Bandyopadhyay TK
Recent Pat Biotechnol; 2019; 13(1):33-44. PubMed ID: 30318009
[TBL] [Abstract][Full Text] [Related]
16. Critical overview of the main features and techniques used for the evaluation of the clinical applicability of L-asparaginase as a biopharmaceutical to treat blood cancer.
Costa-Silva TA; Costa IM; Biasoto HP; Lima GM; Silva C; Pessoa A; Monteiro G
Blood Rev; 2020 Sep; 43():100651. PubMed ID: 32014342
[TBL] [Abstract][Full Text] [Related]
17. Molecular cloning, characterization, and in-silico analysis of l-asparaginase from Himalayan
Kumar S; Darnal S; Patial V; Kumar V; Kumar V; Kumar S; Singh D
3 Biotech; 2022 Aug; 12(8):162. PubMed ID: 35822154
[TBL] [Abstract][Full Text] [Related]
18. Heterologous expression and molecular modelling of L-asparaginase from Bacillus subtilis ETMC-2.
Agrawal S; Jana UK; Kango N
Int J Biol Macromol; 2021 Dec; 192():28-37. PubMed ID: 34610352
[TBL] [Abstract][Full Text] [Related]
19. Expanding targets for a metabolic therapy of cancer: L-asparaginase.
Covini D; Tardito S; Bussolati O; Chiarelli LR; Pasquetto MV; Digilio R; Valentini G; Scotti C
Recent Pat Anticancer Drug Discov; 2012 Jan; 7(1):4-13. PubMed ID: 21854356
[TBL] [Abstract][Full Text] [Related]
20. Glutaminase Activity of L-Asparaginase Contributes to Durable Preclinical Activity against Acute Lymphoblastic Leukemia.
Chan WK; Horvath TD; Tan L; Link T; Harutyunyan KG; Pontikos MA; Anishkin A; Du D; Martin LA; Yin E; Rempe SB; Sukharev S; Konopleva M; Weinstein JN; Lorenzi PL
Mol Cancer Ther; 2019 Sep; 18(9):1587-1592. PubMed ID: 31209181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
